Virobay Facts

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more

2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more

2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more

2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more

2010 – Virobay closes Series B financing

2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple development candidates are poised for Phase I

2007 – In-licensed cathepsin protease inhibitor assets

2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C

2006 – Founded as a protease inhibitor drug discovery and development company

more

Publications and Presentations

Poster Presentation, AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, November 2011, San Francisco, USA

Leslie J. Holsinger, Alysia Ondoua-Lozano, Jade Rodriguez, Katherine Hanlon, Edward J. Bilsky, Joshua Havelin, Jeffrey M. Dener, Robert Booth, Todd W. Vanderah

Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer

Download PDF

Poster Presentation, AASLD Annual Meeting, November 2010, Boston, USA

Leslie J. Holsinger, Dion F. Coakley, Jeffrey M. Dener, Michael J. Green, Robert Booth, Stacie A. Dalrymple

Efficacy of a Reversible Cathepsin B Inhibitor in a Rodent Model of Liver Fibrosis and Human Pharmacokinetic Profile

Download PDF

Poster Presentation, Pain 2010: Bench to Bedside Frontiers of Clinical Investigation Symposium, October 2010, San Diego, CA. USA

Leslie J. Holsinger, John Grist, Anna K. Clark, Robert Booth, Marzia Malcangio, Stacie A. Dalrymple

Systemic Inhibition of Cathepsin S Attenuates Hypersensitivity in Animal Models of Neuropathic and Inflammatory Pain

Download PDF

Biochimie. 2010 May 4. [Epub ahead of print]

Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA

Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model

Poster Presentation, Society for Neuroscience, October 2009, Chicago, USA

Stacie A. Dalrymple, John Grist, Anna K. Clark, and Marzia Malcangio

Systemic Inhibition of Cathepsin S Attenuates Vincristine-Induced Neuropathic Hypersensitivity

Download PDF

Poster Presentation, Society of Investigative Dermatology, May 2009, Montreal, Canada

Leslie J. Holsinger, Simonetta Mocci, John O. Link, Kyle Elrod ,Michael J.  Green, Robert Booth, Stacie A. Dalrymple

Characterization of VBY-129, a Cathepsin S Inhibitor Efficacious in a Mouse Model of Psoriasis

Download PDF

Oral Presentation: The American Pain Society Annual Meeting, May 2009, San Diego CA. USA

Stacie A. Dalrymple, Nigel Calcutt, Teresa Mixcoatl-Zecuatl, John Grist, Marzia Malcangio, John Link

A selective cathepsin S inhibitor, VBY-285, reverses allodynia in a rat model of diabetic neuropathy